Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

MLA

Rusconi, S., et al. “Loss of Antiviral Effect Owing to Zidovudine and Lamivudine Double Resistance in HIV-1-Infected Patients in an Ongoing Open-Label Trial.” Antiviral Therapy, vol. 2, no. 1, Jan. 1997, pp. 39–46. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=11322265&authtype=sso&custid=ns315887.

APA

Rusconi, S., De Pasquale, M. P., Milazzo, L., Moscatelli, G., Bulgheroni, E., Citterio, P., d’Arminio-Monforte, A., Moroni, M., & Galli, M. (1997). Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial. Antiviral Therapy, 2(1), 39–46.

Chicago

Rusconi, S, M P De Pasquale, L Milazzo, G Moscatelli, E Bulgheroni, P Citterio, A d’Arminio-Monforte, M Moroni, and M Galli. 1997. “Loss of Antiviral Effect Owing to Zidovudine and Lamivudine Double Resistance in HIV-1-Infected Patients in an Ongoing Open-Label Trial.” Antiviral Therapy 2 (1): 39–46. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=11322265&authtype=sso&custid=ns315887.